Study shows promising results for immunotherapy targeting skin cancer
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
Apr 25, 2023
0
72
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
Apr 25, 2023
0
72
Even as pancreatic cancer treatments improve, only about 9% of patients survive past five years. Researchers have searched unsuccessfully to find genetic differences that explain why some patients survive long term and some ...
Apr 3, 2023
0
72
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from ...
Mar 30, 2023
0
21
For the first time, a research team has identified and analyzed the steps by which immune cells "see" and respond to cancer cells, providing insights into reasons some treatments may be effective for certain patients but ...
Mar 8, 2023
0
55
Thanks to a new prognostic method for detecting cancers including cancer of the large intestine, doctors could provide clearer disease prognoses and predict which patients will respond best to immunotherapy. The method consists ...
Feb 9, 2023
0
63
A new clinical and preclinical study from UCLA Jonsson Comprehensive Cancer Center identifies the DNA roots of resistance to targeted cancer therapy, providing a possible strategy to address a vexing issue in cancer therapeutics. ...
Jan 26, 2023
0
51
Immunotherapies have improved outcomes of many patients with cancer, including melanoma. But these therapies work for only a subset of patients. Numerous studies are looking at improving responses, including research focusing ...
Jan 23, 2023
0
56
Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality.
Nov 10, 2022
0
1454
Most deaths from melanoma—the most lethal form of skin cancer—occur in patients who were initially diagnosed with early-stage melanoma and then later experienced a recurrence that is typically not detected until it has ...
Oct 31, 2022
0
34
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers ...
Oct 26, 2022
0
55